Drug intelligence / Profile preview

Human RMC Therapeutic Vaccine

Development stage
Preclinical
Lead developer
Calviri
Modality
Peptides, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The Human RMC Therapeutic Vaccine is an off-the-shelf cancer vaccine being developed by Calviri for the treatment of renal medullary cancer (RMC), a rare and aggressive malignancy. It is based on the proprietary RNA-Error Derived Neoantigens (REDNs) platform, which identifies shared frameshift peptides generated by tumor-specific RNA processing errors. Unlike personalized neoantigen vaccines, this therapeutic is designed as a pre-made product targeting antigens common across RMC patients. The vaccine is currently in development, with plans for a first-in-human clinical trial in collaboration with MD Anderson Cancer Center.

Other names
RMC Therapeutic VaccineRMC Therapeutic Vaccine-Calviri-therapeutic vaccine-RMC
02

Targets

REDN (RNA-error derived neoantigen frameshift peptide)

Beyond the preview

Go deeper on Human RMC Therapeutic Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human RMC Therapeutic Vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call